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ABSTRACT 
 
 
Many signaling pathways have been shown to be involved in the formation of the 
vascular system.  Among them are the endothelial specific receptor families such as VEGF, 
Ang/Tie, as well as other signaling pathways such as semaphorins, which are also involved, 
in axonal guidance.  It is known that the interaction between receptor tyrosine kinase, Tie2, 
VE-Cadherin, and VE-PTP mediate endothelial cell quiescence and adhesion. However, the 
structural basis of these interactions is not well understood.  The aim of our study is to 
characterize the binding interactions between these players.  Another important part of 
our study is describing the cross-talk between vasculature and nervous system by 
characterizing the Neuropilin/Plexin/Semaphorin system.  VE-Cadherin along with 
neuropilins plays an essential role by directing VEGF signals to the appropriate location 
and coordinating the activation of downstream molecules.   
We characterize the interaction between Tie2, VE-PTP and VE-Cadherin by (FRET)-
based proximity assay, fluorescence lifetime imaging, and co-immunoprecipitation assays. 
Our data showed a consistent localization of the protein and FRET signal for Tie2 and VE-
PTP prior to ligand recognition. We showed the association between Tie2 and VE-Cadherin 
complex by co-immunoprecipatation.  However, our FRET data was not consistent.  The 
examination of VE-PTP and VE-Cadherin for association and localization of the protein 
showed a very unique, mutually exclusive localization of the protein. Our study of 
Neuropilin/Plexin/Semaphorin system showed changes in the protein localization, FRET 
signal and morphology upon stimulation of HEK293 cells expressing Nrp/plexin with 
 
 
Sema3D.  In this system VE-Cadherin along with neuropilins plays an essential role by 
directing VEGF signals to the appropriate location and coordinating the activation of 
downstream molecules.  The characterization of extracellular binding between Tie2, VE-
PTP, and VE-Cadherin, will help to better understand the molecular mechanisms of normal 
and tumor angiogenesis to develop new anti-angiogeneic therapies.   
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Chapter 1 
 
Introduction 
 
 
1.1 Blood Vessel Development  
 
The formation of the vascular system is one of the earliest and most important 
events that occur in the developing embryo providing the growing organism with 
oxygen and nutrients as well as removing the waste products.  Vasculogenesis and 
angiogenesis are two distinct processes that are required for the development of the 
vascular system. Vasculogenesis is the process of the de novo formation of blood vessels 
that consists of two distinct events: one is production of new endothelial cells in a 
developing embryo and second is the formation of blood vessels in adult avascular 
tissue area from precursor cells (hemangioblasts) which eventually differentiate into 
vascular precursors (angioblasts).  These angioblasts migrate, coalesce into cords and 
assemble into a primary capillary plexus which expresses endothelial specific markers 
such as vascular endothelial protein tyrosine phosphatase (VE-PTP), vascular 
endothelia growth factor receptor 2 (VEGFR2), Tie1,  Tie2, and vascular endothelium 
(VE)-cadherin (Nawroth, 2002; Moser et al., 2012).  Angiogenesis is the process of 
formation of new blood vessels from already existing  vessels by three mechanisms- 
non-sprouting (intussusceptive), sprouting, and stretching of existing vessels through 
mechanical forces (looping).  The difference between the non-sprouting and sprouting 
mechanisms is that non-sprouting angiogenesis does not rely primarily on proliferation 
of endothelial cells during embryonic development. In contrast, sprouting angiogenesis 
depends on cell proliferation and occurs relatively slower (Makanya et al., 2008).
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The formation of new blood vessels occurs through sprouting and looping.  The 
understanding of looping mechanisms is very limited since it was only identified recently 
(Kilarski et al., 2009).   
In this dynamic network of blood vessels, endothelial cells that line the vascular wall 
control the permeability of these blood vessel walls.  The normal vascular permeability 
contributes to normal angiogenesis, blood pressure control, as well as immune responses.  
Abnormal increase in vascular permeability is often observed in many pathological 
conditions and human diseases, such as brain stroke, allergy, inflammation, and tumor-
induced angiogenesis (Prager et al., 2012).   
 
1.2 Tumor Angiogenesis  
 
It is easy to forget that cancer is not a single disease, but instead hundreds of 
diseases that involve variety of molecules and signaling pathways.  It starts when a cell 
from any part of our body starts multiplying out of control for no good purpose and, if there 
is no restraint, sooner or later it will create a mass of tissue called a tumor. 
Angiogenesis and tumor progression are closely linked to each other.  Just as 
embryo during development, tumor cells require a sufficient amount of blood vessels that 
supply nutrients and oxygen for their growth and expansion (Hanahan  et al., 2006).  In the 
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absence of angiogenesis, tumor is an avascular mass, and can remain in the state of 
dormancy for years.  The tumor is referred to as the “angiogenic switch” (Bergers et al., 
2003) when it becomes angiogenic.  This switch is initiated when the balance between pro-
angiogenic and anti-angiogenic factors is in favor of the pro-angiogenic molecules such as 
VEGF and Ang-2.  This unbalance is triggered by genetic mutations, metabolic or 
environmental factors such as hypoxia  (Carmeliet et al., 2000).  In addition to genetic and 
epigenetic changes, the “angiogenic switch” is a process that allows rapid tumor 
progression. This increase in tumor vasculature can occur at any stage of tumor 
development depending on the tumor type and the environment.  The temporal and spatial 
expansion of molecules that are involved in angiogenesis is not well regulated, leading to 
an unorganized and functionally abnormal vasculature (Figure 1).  The understanding of 
how normal and tumor angiogenesis is regulated by these agniogenic factors is important 
to deveolopment of anti-cancer drugs.  For example anti-cancer drug, Bevacizumab (trade 
name Avastin) is a humanized monoclonal antibody that inhibits the major pro-angiogenic 
factor, vascular endothelial growth factor A (VEGF-A) (Heinke et al., 2012). 
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Figure 1: Tumor Angiogenesis.  Following somatic mutation (1) a small collection of 
tumor cells form that are avascular and remain dormant (2).  The unbalance between 
activators and inhibitors of angiogenesis results in “angiogenic switch” and release of 
angiogenic factors (3) that stimulate rapid tumor growth via forming a mass of new blood 
vessels (4). 
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1.3 Endothelial Cell quiescence and Adhesion  
Pathological conditions such as inflammation, hypoxia and thrombosis are 
associated with increased vascular permeability.  Endothelial cells possess several 
molecular mechanisms by which this permeability can be regulated.  In mature vessels, the 
endothelium is quiescent and cells adhere tightly to each other resulting in inhibition of 
proliferation and a leak resistant vessel (Hordijk  et al. 1999).  Under these conditions cells 
are less sensitive to growth factors such as VEGF, angiopoietin-1 (Ang-1) and fibroblast 
growth factors (FGFs) and are protected from apoptosis.  This condition is called 
endothelial cell quiescence and maintained at site of cell-cell junctions. The ability to 
adhere is one of the most important characteristics of endothelial cells and regulated by the 
proteins in adherens junctions (AJs) and tight junctions (TJs) (Taddei et al., 2008).  Tight 
junctions seal adjacent epithelial cells in a narrow band just beneath their apical surface 
whereas adherens junctions provide strong mechanical attachments between adjacent cells 
and responsible for contact inhibition.   AJs are primarily composed of VE-cadherin, which 
is capable of clustering and plays a vital role in endothelium integrity and regulates 
vascular permeability (Montera-Balaguer et al., 2009). Structurally, VE-cadherin consists of 
5 extracellular domains, a transmembrane domain, and a cytoplasmic tail.  The short 
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cytoplasmic tail acts as a docking site for signal-transduction molecules and the external 
domain regulates hemophilic interactions.  VEGF is a fundamental regulator of  vascular 
permeability through downstream signaling mechanisms.  It has been shown that the 
binding of VEGF to its receptor VEGFR-2 activates the downstream phosphorylation of VE-
cadherin and causes it to translocate from of cell-cell junctions thereby decreasing 
adhesive properties and enhancing permeability (Gavard et al., 2006). The primitive 
vascular plexus is formed in the absence of VE-cadherin, however mice that are null for VE-
cadherin gene have major defects in vascular development, which results in embryo 
lethality around 9.5-10.5 E (Montera-Balaguer et al., 2009).  In addition to being linked to 
VEGF receptors, VE-cadherin interacts with the endothelial receptor-type protein tyrosine 
phosphatase VE-PTP through their extracellular domains and enhances its adhesive 
function (Broermann et al., 2011).  In the absence of VE-PTP, cell layer permeability 
enhances and VE-cadherin adhesive function decreases (Nottebaum et al., 2008).  The fact 
that in VEGF stimulated cells VE-PTP dissociates from VE-cadherin, suggests that a precise 
balance is needed between the VEGF and VE-PTP to control the endothelial barrier 
integrity of VE-cadherin (Figure 2).  These findings suggest that both VEGF and VE-PTP are 
attreactive targets in treatment of pathological vascular permeability.   
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 VE-PTP is found to associate with another cell surface membrane protein, Tie-2 that 
binds to the cytoplasmic phosphatase domain of VE-PTP and it is shown to 
dephosphorylate VE-PTP (Figure 2) (Baumer et al., 2006). Like VEFGRs, Tie-2 is a receptor 
tyrosine kinase (RTK), which is vital to the formation of blood vessels during the 
development and tumor angiogenesis. Structurally, RTKs consist of an extracellular ligand 
binding domain, a single transmembrane helix, a juxtamembrane domain, a cytoplasmic 
kinase domain and a C-terminal tail composed of multiple phosphorylatable tyrosines 
(Hubbard et al., 2007).  RTK’s have evolved many signaling mechanisms that consist of cell 
surface protein receptors which serve to transduce signals from extracellular part of the 
cell to the inside of the cell.  They initiate intacellular signals via their ability to 
phosphorylate themselves and other cytoplamic proteins on tyrosine residues.  Thus, 
understanding of how VE-PTP negatively regulates RTK’s has important therapeutic 
implications.   
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Figure 2: Schematic Representation outlining the molecular mechanism regulating 
the integrity of endothelial cell-cell contacts.  Ang1 translocates Tie2 to cell-cell 
contacts, which in turn, promotes VE-PTP translocation to cell junctions. Here at cell-cell 
contacts, VE-PTP dephosphorylates Tie2 and VEGFR-2, which leads to inhibition of VEFGR-
2 phosphorylation of VE-Cadherin resulting in increased stability of endothelial cell 
junctions and reduced permeability.   
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Vestweber, D., Winderlich, M (2008). Cell adhesion dynamics at endothelial junctions: VE-
Cadherin as a major player.Trends in Cell Biology. Vol. 19. No1.   
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1.4 The VEGF/VEGFR/Neuropilin/Plexin/Semaphorin system 
The cardiovasculature and nervous system form a highly branched network 
extending to every part of the body.  VEGF signaling has crucial effects on cross-talk 
between the two systems, but these signaling mechanisms must be regulated on many 
levels to ensure the correct biological outcome (Heinke et al., 2012).  Co-receptors such as 
neuropilins (Nrp) and (VE)-cadherin direct VEGF signals to the appropriate location and 
coordinates the activation of downstream molecules (18).  Nrps (Nrp-1 and Nrp-2) are 
single-pass transmembrane proteins with a large extracellular domain and a short 
cytoplasmic domain that presents a PDZ binding site. Having a very short cytoplasmic 
domain, Nrps are not able to transduce cell signals on their own and therefore, act as co-
receptors and require plexins for signaling. They were initially characterized as non-
tyrosine kinase receptors that mediate axon guidance and neuronal development through 
class-3 semaphorins.  Now it is clear that Nrps are expressed by variety of cells including 
EC and associate with normal and disease-associated blood vessel formation (Prahst et al., 
2008). The ability of Nrps to bind to two structurally and functionally unrelated ligands, 
VEGF and semaphorins, suggests a dynamic interaction between angiogenesis and nervous 
system.  Semaphorins belong to a large family of cell-associated and secreted proteins 
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characterized by an extracellular N-terminal sema domain and a cysteine rich PSI (plexin, 
semaphoring, and integrin) domain.  They mainly function as chemorepellents that direct 
axons away from the tissues marked by their expression though in some cases they act as 
chemoattractants.  Plexins are a large family for cell surface receptors for semaphorins.  
Similarly, they contain a sema domain in the extracellular portion as well as (in general) 
three copies of PSI domains and three IPT.  Like Nrps, plexins are also widely expressed in 
vasculature and nervous system. 
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Chapter 2 
 
Methods 
 
2.1 Cell Manipulations and Transfections 
Human Embryonic Kidney 293 ( HEK293) and human osteosarcoma cell line (U2OS)  
cells were cultured in  Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) 
supplemented with 10% Fetal Bovine Serum (FBS) (Serum Source International) and 5% 
Pen/Strep (Invitrogen).   Transfections were performed in complete medium lacking the 
antibiotics.  Cells were consistently transfected at 70-90% using Lipofectamine 2000 
(HEK293) or FuGENE HD (U2OS) and Opti-MEM (Invitrogen) according to the protocol 
provided by Lipofectamine 2000 kit.  In all co-expression experiments the ratio of each 
construct was 1:1.  
2.2 Cellular Imaging 
For the analysis of interactions, in which two separate molecules are labeled with an 
appropriate pair of fluorophores, an interaction can be shown by observing FRET (the two 
molecules must be in close proximity (~10nm), the emission spectrum of the donor must 
overlap with the excitation spectrum of the acceptor, and the emission dipole moment 
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must not be orthogonal to the acceptor absorption dipole moment). By using fluorescence 
imaging microscopy, one can visualize the location of green fluorescent proteins within a 
living cell and follow the time course of the changes in FRET corresponding to cellular 
events at a millisecond time resolution. The observation of such dynamic molecular events 
in vivo provides vital insight into the action of biological molecules (Periasamy et al., 2005).  
Cell imaging was performed 24-48 hours post-transfection using Zeiss Observer Z1 
wide-field microscope equipped with violet HeNe (405 nm), Argon (458, 488, 514 nm), 
green laser (561nm), orange (594 nm), red HeNe (633 nm).  The system includes mercury 
arc lamp excitation, a Zeiss AxioCamMRm CCD camera with 12-bit dynamic range, fully 
automated xyz stage, a glycerin-immersion objective lens, 63x. In all experiments, the 
conditions for live cells were 37°C and 5% CO2 humid atmosphere.  Fluorophore-protein 
fusions were imaged using excitation and emission wavelengths of 433 nm and 527 nm for 
mTQ and sYFP2 respectively.  The AOTF’s for 433 nm and 527 nm were set to 100% and 
25% respectively to eliminate cross talk between the two channels.  The FRET efficiency is 
calculated using precision FRET (pFRET) algorithm which performs pixel-by-pixel signal 
bleed-through (SBT) correction resulting in removal of donor and acceptor SBT on the 
basis of matched fluorescence levels between double and single labeled specimens (21).   
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 The failure to detect FRET from a pair of labeled proteins may not always mean the 
absence of interaction between them.  Because this detection signal relies on the efficiency 
of FRET and choosing a donor fluorophore that has a significant overlap with the acceptor 
absorption is important.  When measuring living cells, one of the challenges is the 
concentration dependence of the measured proteins, determination of which is practically 
impossible in living cells.    Another limitation of FRET is the intensity, which is more prone 
to artifacts at weaker energy transfer signals.  Lifetime imaging of the donor and acceptor 
fluorophores offer significant improvement in sensitivity for determining the physical 
interaction between the proteins.  Fluorescence lifetime imaging monitors lifetime 
independent of local fluorophore concentrations and intensity but sensitive to 
environmental conditions such pH and ion concentration (Gardella et al., 1993). One of the 
limitations is the existence of different lifetimes which makes FRET determination using 
FLIM very difficult in living cells. 
For fluorescence lifetime imaging we used Zeiss LSM 510 META NLO multi-photon 
laser scanning microscope (fixed stage upright) with internal (descanned) detectors 
(including the META detector), two direct (non-descanned) detectors, a transmitted light 
detector and a Becker & Hickl Fluorescence Lifetime Imaging system with 2 hybrid GaAsP 
detectors (for FRET-FLIM). The system has four lasers: a Spectra-Physics Mia-Tai 
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broadband tunable Ti:sapphire laser (710-990 nm) for multi-photon imaging, as well as 
Argon (458, 476, 488, 514 nm), 561 diode (561 nm), and red HeNe (633 nm).  We analyzed 
the lifetime data measured by Fluorescence Lifetime Imaging (FLIM) using SPCImage 3.2 
(Becker & Hickl).  This software analyzes the raw data using an exponential model function.  
During the fitting process, the chi-square value between the data and the model function is 
minimized.   
 
2.3 Immunoprecipitation studies 
HEK293 were seeded in 10 cm dishes and allowed to grow to 80-90% confluence.  
Prior to transfection the media was changed to DMEM medium without penicillin. Cells 
were transfected with Lipofectamine and Opti-MEM (Invitrogen) according to the protocol 
provided by Lipofectamine 2000 kit with the appropriate vector DNA.  After 48 hours the 
transfected cells were washed briefly and gently with PBS.  Whole cell lysates were 
harvested by adding lysis buffer (20 mM Hepes, 150 mM NaCl, 1 mM EDTA, 1% NP-40 
detergent, 1 mM Sodium Orthovanadate, complete protease inhibitor (Roche), and 1.2 
mg/mL Aprotinin (Sigma-Life Science).  To get rid of cellular debris the cell lysate was 
centrifuged for 10 minutes at 15, 000 rpm and the supernatant was collected for 
17 
 
immunoprecipatation.  Lysates were precipitated with Protein A agarose beads and 
incubated with Tie2, VE-Cadherin or myc  antibodies (depending on the experiment 
performed) overnight at 4C.  After washing with HBST and HBS, bounded protein was 
eluted from the beads by boiling in 2x Sample Buffer (10 mM Tris pH8.0, BM-t, 1% 
bromophenol).  Cell lysates and elutes from Protein A beads were separated by 10% SDS-
PAGE gel electrophoresis and electrotransferred to a nitrocellulose membrane (VWR).  The 
membrane was blocked with milk for 1 hour and then probed with primary monoclonal 
antibody in TBST ( 10 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween20) overnight.  After a 
15 minutes wash with TBST, the blot was probed with secondary antibody coupled to HRP 
for 1 hour.  The blot was developed with the chemiluminescent substrate (Pierce).  
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Results 
 
Chapter 3 
 
VE-PTP and Tie2 complex formation 
 
 To observe the localization and extracellular interaction between VE-PTP and Tie2, 
we transiently expressed full length VE-PTP and VE-PTP lacking the phosphatase domain 
with Tie2 lacking the tyrosine kinase domain in transfected human embryonic kidney cell 
line (HEK293). The proteins were tagged with fluorophores and the localization was 
monitored using a Zeiss Observer Z. 1 wide-field microscope coupled with fluorescence 
resonance energy transfer (FRET)-based proximity assay.  The Tie2 construct was fused 
with a cyan fluorescent protein donor (mTurquoise-mTQ) to the carboxy termini in place of 
the catalytic tyrosine kinase domain and a yellow fluorescent protein acceptor (sYFP2) was 
linked to the carboxyl terminus of a full-length VE-PTP ectodomain construct (phosphatase 
domain present). Figure 3.1 depicts that energy transfer between the donor (mTQ) and 
acceptor (sYFP2) only occurs if the receptors are in close proximity (<10nm) which results 
in emission of sYFP2 following excitation of mTQ.  The FRET efficiency is calculated using 
the precision FRET (pFRET) algorithm (developed by Ammasi Periasamy) which performs 
pixel-by-pixel signal bleed-through (SBT) correction resulting in removal of donor and 
acceptor SBT on the basis of matched fluorescence levels between double and single 
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labeled specimens (Elangovan et al., 2003).  Figure 3.2 A illustrates a representative image 
of fluorescence intensity and membrane localization of VE-PTP-full length (FL)-sYFP2 and 
Tie2-mTQ.  Based on our FRET-based proximity we are able to observe VE-PTP-FL and 
Tie2 of an average FRET efficiency value of 15.2 ± 0.89 SEM.  This FRET signal suggests that 
the ectodomain of VE-PTP and Tie2 interact.  We observed this association in the absence 
of angiopoietin ligand demonstrating that VE-PTP-FL and Tie2 form complex prior to 
ligand recognition.  In addition to examining VE-PTP-FL, we also looked at the VE-PTP-
FRET (Figure 3.2 B) construct, which lacks the phosphatase domain.  Similarly, the protein 
was co-localized uniformly but did not interact based on the FRET efficiencies were 
significantly lower.  To make sure that the strong FRET signal between VE-PTP-FL and Tie2 
was not due to over-expression, we co-expressed Tie2 receptor with the functionally 
unrelated receptor Plexin-YFP shown in Figure 3.3 B and observed a 5.3% FRET efficiency 
(negative control was generated by another member of the lab, Annamarie Dalton).  These 
findings suggest that the association between VE-PTP and Tie2 is specific and that FRET 
efficiency observed is not due to overexpression and nonspecific interaction.  For the 
positive control Tie2-CFP construct was transiently transfected into HEK293 with Tie1-
YFP.  This known association between Tie2 and Tie1 gave a very high FRET efficiency of 
66.4±2.8 SEM (Figure 3.3B). 
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To confirm the association between Tie2 and VE-PTP with another technique we 
performed Fluorescence Lifetime Imaging (FLIM) using SPCImage 3.2 software (Becker & 
Hickl).  When measuring living cells, one of the challenges is the concentration dependence 
and different intensities of the fluorophores. However, fluorescence lifetime imaging 
monitors lifetime independent of local fluorophore concentrations and intensity but 
sensitive to environmental conditions such pH and ion concentration (Gardella et al., 
1993).  The viability of live-cells is critical when using high intensity light sources such as 
lasers.  Although, high speed time-gated FLIM reduces light that gets to cells, 
measurements at very low light affect quantitative FLIM results.  In two component FRET 
system, non-radiative energy transfer occurs from donor to acceptor if they are in close 
proximity and the fluorescence lifetime of the donor decreases.  Figure 3.4 illustrates the 
lifetime data for Tie2-mTQ alone (A) and Tie2-mTQ co-expressed with VE-PTP (B).  In 
average the lifetime of the double labeled cells does not decrease in our experiments (2.9 
ns for both donor alone and donor in the presence of acceptor).  Since numerically our 
lifetime data did not confirm the interaction between Tie2 and VE-PTP, we ran both the 
donor alone and the double labeled cells as monoexponential decay to show that the 
lifetime distribution histogram clearly indicates that the donor in the presence of the 
acceptor is not monoexponential decay.  This ”shoulder like” peak observed in the 
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histogram suggests the quenching of the donor and the possible occurrence of FRET 
between VE-PTP and Tie2.  In addition, we have made several attempts to show the 
interaction between Tie2 and VE-PTP by co-immunoprecipitation assays.  HEK293 cells, 
which lack endogenous Tie2 and VE-PTP receptors, were transiently transfected with Tie2-
myc alone, VE-PTP-myc alone or a combination of two.  As seen in Figure 3.5A, western 
blotting of whole cell lysates with anti-myc antibodies demonstrate expression of Tie2, VE-
PTP and both in combination.  The co-immunoprecipitation of Tie2, VE-PTP and both Tie2 
and VE-PTP are shown in 3.5 B (total protein loaded in each lane was 1 mg).   All three 
were IP’ed with Tie2 antibody and probed with anti-myc and therefore we expected to 
observe Tie2 expression (lane 1) and no VE-PTP expression (middle lane).  When both Tie2 
and VE-PTP were co-expressed (lane 3), we expected to see two bands (one for Tie2 and 
one for VE-PTP) since both constructs were fused to myc, IP’ed with Tie2 antibody and 
probed with myc.  The relative ratio was determined and the calculated value was 
arbitrarily set equal to 1.0 for VE-PTP alone.  Values are graphically displayed below each 
respective lane.   
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Figure 3.1: Schematic Representation of FRET-based proximity assay of interaction 
between VE-PTP and Tie2.  The extracellular domains are fused to GFP variants, the VE-
PTP construct tagged with sYFP2 and Tie2 tagged with mTQ.  Due to the proximity of the 
receptors, upon excitation of mTQ at 433nm, non-radiative energy transfer occurs to 
sYFP2, resulting in sYFP2 emission. 
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Figure 3.2: In vivo FRET images of VE-PTP-Tie2 interaction. Tie2-mTQ construct was transiently 
transfected into HEK293 with VE-PTP-FL-sYFP2 (A) or VE-PTP-FRET-sYFP2 (B).  FRET efficiency 
values were determined within the regions of interest (ROI) and averaged with ±SEM.   
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0                                              45 
FRET efficiency 
15.2 ± .89% SEM 
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Tie2-mTQ                                       VE-FRET-sYFP2                           Merged                 
 
 
 
 
 
 
 
0                                          45          
FRET efficiency 
 2.9 ± .92% SEM 
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Figure 3.3: In vivo FRET images positive and negative controls.  A) Tie2-CFP construct was 
transiently transfected into HEK293 with Tie1-YFP as a positive control.  B) Tie2-mTQ and 
Plexin-YFP were transiently transfected into HEK293 as a negative control.  FRET efficiency 
values were determined within the regions of interest (ROI) and averaged with ±SEM.   
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Figure 3.4: The lifetime data of Tie2-mTQ and VE-PTP.   Tie2-mTQ alone (A) and Tie2-mTQ co-
expressed with VE-PTP (B) measured by Fluorescence Lifetime Imaging (FLIM) using SPCImage 
3.2 software (Becker & Hickl).   
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 Figure 3.5:  Cell Lysate and Immunoprecipitation of Tie2 and VE-PTP.  (A) Cell Lysate 
of Tie2 alone, VE-PTP alone and both combined.  (B) HEK293 cells were transfected with 
Tie2-myc alone, VE-PTP-myc alone or both proteins combined, harvested and lysates 
probed with anti-myc.  The relative ratio was determined and the calculated value was 
arbitrarily set equal to 1.0 for VE-PTP alone.  Values are graphically displayed below each 
respective lane.   
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Chapter 4 
 
VE-Cadherin and Tie2 complex formation 
 
 To observe the localization and extracellular interaction between VE-Cadherin and 
Tie2 in vivo similar FRET assay as described above for VE-PTP and Tie2 was used.  Both 
proteins were linked to GFP variant fluorophores to visualize the localization.  The Tie2 
construct was fused with a cyan fluorescent protein donor (mTurquoise-mTQ) and a 
yellow fluorescent protein acceptor (Venus) was linked to the VE-Cadherin construct. Both 
proteins were expressed in    transiently transfected HEK293 and imaged to look for the 
occurrence of FRET.  The FRET efficiency is calculated similarly using precision FRET 
(pFRET) algorithm.  Couple different scenarios were observed with this complex.  We saw a 
co-localization with FRET efficiency of 14.9±1.3 SEM which suggests a possible association 
between of VE-Cadherin and Tie2. However, we also observed the protein not co-localizing 
in cells co-expressed with these two constructs.  Figure 4.1 illustrates the protein co-
localizing with FRET signal of 14.9±1.3 SEM in not a confluent dish (A) or at cell-cell 
junctions (B).  We also saw the protein not co-localizing at either confluent (data not 
shown) or cell-cell junction (C).  Our studies in U2OS suggested no interaction between VE-
Cadherin and Tie2 since the protein did not co-localize and therefore there was no FRET 
signal (4.1D).  Figure 4.2 illustrates the lifetime data for Tie2-mTQ alone (A) and Tie2-mTQ 
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co-expressed with VE-Cadherin-Venus (B). In average the lifetime does not decrease in our 
experiments (2.9 ns for both donor alone and donor in the presence of the acceptor). 
However, although we ran both the donor alone and the double labeled cells as 
monoexponential decay, the lifetime distribution histogram clearly shows that the donor in 
the presence of the acceptor is not monoexponential decay.  This ”shoulder like” peak 
observed in the histogram suggests the quenching of the donor and the possible occurrence 
of FRET between VE-Cadherin and Tie2.  We were able to show the interaction between 
VE-Cadherin and Tie2 by co-immunoprecipitation assays shown in Figure 4.3.  Telomerase-
immortalized human microvascular endothelial (TIME) cells which has endogenous VE-
Cadherin and Tie2 were harvested, lysed, and probed with anti-Tie2 (4.2A)  As expected, 
we were able to observe Tie2 expression in whole cell lysate (lane 3) and no expression in 
the negative control (middle lane).  Lane 1 was IP’ed with VE-Cadherin antibody, probed 
with Tie2. The reciprocal was performed with anti-VE-Cadherin antibody.  Similarly, we 
were able to express VE-Cadherin (lane 1) and observed no expression in the negative 
control (middle lane).   The relative ratio was determined and the calculated value was 
arbitrarily set equal to 1.0 for the negative control.  Values are graphically displayed below 
each respective lane (total protein loaded for IP was 1mg).   
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Figure 4.1: In vivo FRET images of VE-Cadherin-Venus with Tie2 interaction. Tie2-
mTQ construct was transiently transfected into HEK293 with VE-Cadherin-Venus showing 
co-localization of the protein on the cell membrane (A) or at cell-cell junction (B) or no co-
localization (C).  Tie2-mTQ construct was transiently transfected into U2OS with VE-
Cadherin-Venus showing no co-localization (D).  FRET efficiency values were determined 
within the regions of interest (ROI) and averaged with ±SEM.   
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Figure 4.2: Lifetime data of Tie2 and VE-Cadherin.  Tie2-mTQ alone (A) and Tie2-mTQ co-
expressed with VE-Cadherin-Venus (B) measured by Fluorescence Lifetime Imaging (FLIM) using 
SPCImage 3.2 software (Becker & Hickl).   
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Figure 4.3:  Immunoprecipitation of VE-Cadherin and Tie2.  TIME cells were harvested, lysed, 
and probed with anti-Tie2 (A) and the reciprocal was performed with anti-VE-Cadherin (B).  The 
relative ratio was determined and the calculated value was arbitrarily set equal to 1.0 for the 
negative control.  Values are graphically displayed below each respective lane.   
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Chapter 5 
 
VE-Cadherin and VE-PTP complex formation 
 
We performed similar assay to examine the localization and extracellular 
interaction between VE-Cadherin and VE-PTP in vivo.  We examined few differently tagged 
constructs of VE-PTP and VE-Cadherin and all showed a very unique mutually exclusive 
localization of the protein.  VE-PTP-FL-mTQ was co-expressed with VE-Cadherin-Venus 
showing mutually exclusive localization of the protein when the cells are confluent (5.1 A) 
and mutually exclusive behavior in isolated cells (5.1 B). This unusual mutually exclusive 
localization of the protein was also observed with VE-Cadherin-mTQ co-expressed with VE-
PTP-FL-sYFP2 and VE-FRET-sYFP2 (data not shown).  Figure 5.2 illustrates the lifetime 
data for VE-PTP-FL-mTQ alone (A) and VE-PTP-FL-mTQ co-expressed with VE-Cadherin-
Venus (B).  In average the lifetime does not decrease in our experiments (2.8 ns for bot 
donor alone and donor in the presence of the acceptor).   However, although we ran both 
the donor-acceptor and the donor alone as monoexponential decays, the lifetime 
distribution histogram clearly shows that the double labeled specimen is not 
monoexponential decay.   
In addition, we made several attempts to co-express all three, VE-PTP, VE-Cadherin, 
and Tie2 in HEK293.  VE-PTP-FL-sYFP2 and VE-Cadherin-mTQ were co-expressed with 
Tie2 fused to myc.  We observed mutual exclusive localization of the protein as shown in 
figure 5.3 but unfortunately Tie2-myc appeared to be toxic to cells and we were unable to 
obtain statistically enough data to fully characterize the behavior of the protein.   
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Figure 5.1: In vivo FRET images of VE-Cadherin-Venus and VE-PTP interaction. VE-
Cahdherin-Venus construct was transiently transfected into HEK293 with VE-PTP-FL-mTQ 
showing mutually exclusive localization of the protein in a confluent dish (A) or mutually 
exclusive behavior in isolated cells (B)  FRET efficiency values were determined within the 
regions of interest (ROI) and averaged with +/- SEM.   
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Figure 5.2: The lifetime data of VE-PTP and VE-Cadherin.   VE-PTP-mTQ alone (A) and VE-PTP-
mTQ co-expressed with VE-Cadherin-Venus (B) measured by Fluorescence Lifetime Imaging 
(FLIM) using SPCImage 3.2 software (Becker & Hickl).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
A 
 
 
 
VE-PTP-FL-mTQ 
 
 
B 
 
VE-PTP-FL-mTQ-VE-Cadherin-Venus 
 
46 
 
 
Figure 5.3: In vivo FRET images of VE-Cadherin, VE-PTP and Tie2 interaction.  VE-PTP-FL-sYFP2, 
VE-Cadherin-mTQ and Tie2-myc constructs were transiently transfected into HEK293 showing 
mutually exclusive localization of the protein. 
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Chapter 6 
 
Neuropilin/Plexin/Semaphorin system 
 
We tested several constructs of Nrps and Plexins with various linker lengths to 
obtain the best FRET efficiency signal in HEK293.  In addition to difference in linker size, 
we tested different members of PlexinA family.  Neuropilin-1 with relatively small linker 
size of five residues and Plexin-A1 with nine amino acid residues gave the most reliable 
results. Nrp-1 tagged with mYFP was co-expressed with PlexinA1 tagged with mCFP in 
HEK293.  We observed a co-localization of the protein with FRET efficiency 13.8±5.3SEM  
HEK293 cells expressing Nrp-1 and PlexinA1 were induced with Semaphorin3D (Sema3D) 
and the images were taking every five minutes for one hour.   The role of Sema3D on this 
Nrp/Plexin complex is not well understood.  Based on evidence provided by studies on the 
nature of Nrp-1/Plexin-A1 complex formation, we hypothesized that Sema3D has the 
ability to change the morphology of the cells.  Class 3 semaphorins are known to have a 
high-potency growth cone-collapsing activity in neuronal cells and morphologic changes in 
nonneuronal cells ( Luo et al., 1993; Tamagnone et al., 1999).  Based on our observations, 
Sema3D caused expansion in size and rounding up of Nrp-1/PlexinA1 expressing cells. In 
addition, we observed the protein dissociation and clustering in some parts of the cells as 
shown in figure 6.1.  This morphological change was observed over the first 5-10 minutes 
after the ligand addition.  The addition of Semaphorin3D also induced FRET signal in the 
two experiments we performed.  However, we did not average this increase since in one 
experiment the FRET signal increased by two fold and in the other one by six fold.  The 
FRET signal before adding the ligand was significantly different for both experiments as 
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well.  From our experiments it is clear that addition of Sema3D to Nrp-1/Plexin complex is 
able to mediate the morphologic changes in nonneuronal HEK293 cells.    
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Figure 6:  In vivo FRET imaging of Nrp-1 and PlexinA1 complex induced with 
Semaphorin 3D in HEK293. Nrp-1-mYFP construct was transiently transfected into 
HEK293 with PlexinA1-mCFP.  Semaphorin 3D was added and images were taken every 
five minutes for 60 minutes (the images of every 20 minutes are shown).   
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Chapter 7 
 
Conclusions 
 
 Fluids, cells, nutrients and oxygen are normally exchanged between the blood 
compartments and the surrounding tissues.  In this dynamic network, endothelial cells that 
line the vascular wall control the permeability of these blood vessel walls.  The normal 
vascular permeability contributes to normal angiogenesis, blood pressure control, as well 
as immune responses.  Abnormal increase in vascular permeability is often observed in 
pathological conditions and human diseases, such as tumor-induced angiogenesis, 
inflammation, allergic reaction, and brain stroke.  This vascular permeability is regulated 
by adhesive molecules and receptors that co-localize at cell-cell contacts (Kilarski at el., 
2009).   
What happens when the adhesion molecules meet the receptors?  Receptors such as 
RTK’s are located on the cell surface helping cells to communicate with their environment 
and carry signals to the intracellular machinery.  It used to be known that the binding of 
ligands triggers the activation of the receptors, now it is clear that cell adhesion molecules 
significantly contribute to this activation process (Hanahan at el., 1996).  The 
understanding of this tight collaboration between cell adhesion molecules and RTK’s has 
important therapeutic implications.   
It has been shown that receptors such as VE-PTP and Tie2 regulate permeability 
through its interaction with an adhesive molecule VE-Cadherin.  Ang-1 is an important 
player in this scenario by translocating Tie2 to cell-cell contacts, which, in turn, promotes 
VE-PTP translocation from vesicular compartments in the cell, to the cell-cell contacts. Here 
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at cell-cell contacts, VE-PTP dephosphorylates Tie2 and VEGFR-2 which leads to inhibition 
of VEFGR-2 phosphorylation of VE-Cadherin and inhibition of EC proliferation. The clear 
picture of the role of these players in normal angiogenesis and tumor angiogenesis is still 
unclear. Further investigation of VE-PTP, VE-Cadherin and Tie2 will reveal possible 
applications in treatments of angiogenic diseases (Winderlich at el., 2009).   
It is known that VE-PTP interacts with Tie2 primarily in contacting cells decreasing 
permeability.  For ease of transfection and cellular imaging, we have done most of our 
experiments in HEK293 cells based upon their lack of endogenous Tie2 and VE-PTP 
Vestweber at el., 2008). Our data shows the association between VE-PTP and Tie2 in 
HEK293 with FRET efficiency of 15.2 ± 0.89 SEM, compared to the negative control, which 
gave a result of 5.3% FRET efficiency.  This FRET signal leads us to believe that the 
ectodomain of VE-PTP and Tie2 interact.  As discussed above Ang1 translocates Tie2 to 
cell-cell contacts and therefore Ang1-activated Tie2 decrease permeability by introducing 
more VE-PTP to the intercellular junctions.  We observed VE-PTP-Tie2 association in the 
absence of Ang1 demonstrating that VE-PTP-FL and Tie2 form a complex prior to ligand 
recognition. Our positive control (co-expressed Tie1 and Tie2) gives a very high FRET 
efficiency of 66.4±2.8 SEM (Figure 3.3B) indicating that further biochemical and 
biophysical studies have to be done to characterize the interaction between the Tie2 and 
VE-PTP ectodomains.  One of the essential future directions is to show the formation of VE-
PTP-Tie2 complex in endothelial cells, which express the proteins endogenously.   
 VE-PTP-Tie2 complex formation was also shown using Fluoresecence Lifetime 
Imaging Microscopy (FLIM) which is a powerful tool to map protein-protein interactions in 
living specimens.  As discussed in chapter1 fluorescence lifetime is unaffected by the 
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change in probe concentration or excitation intensity.  However, FLIM is a technically 
challenging technique because it is influenced by any small changes in the cellular 
environment and the existence of different lifetimes makes FRET determination using FLIM 
very difficult in living cells.  Although, it is expected to observe the decrease of lifetime in 
the presence of the acceptor, we were unable to show that numerically.  However, the 
lifetime distribution histogram clearly showed the quenching of the donor in the presence 
of the acceptor, which indicates the possible FRET occurrence between VE-PTP and Tie2.  
Several attempts were made to detect Tie2-VE-Cadherin binding by transiently 
expressing them in HEK293 and performing co-immunoprecipitation assays.  
Unfortunately, despite repeated attempts in changing the concentrations, using different 
constructs and different antibodies, we were unable to show a clear indication of binding of 
these two receptors in transient system.  One of the most promising data was obtained 
when both Tie2 and VE-PTP were fused to myc and we were able to see two bands (one for 
Tie2 and one for VE-PTP) when both were transiently overexpressed in HEK293 and co-
immunoprecipitated (Figure 3.5).    
Among all the mechanisms that regulate vascular permeability of endothelial cells, 
tyrosine phosphorylation plays an essential role.  It is generally accepted that this tyrosine 
phophorylation of VE-Cadherin is observed in weak junctions, which usually leads to 
pathological conditions.  The extent of this phosphorylation is declined when cells reach 
confluency (Lambugnani et al., 1997).  However, the exact mechanism of VE-Cadherin 
phosphorylation has not been fully clarified.  The extracellular interaction between VE-PTP 
and VE-Cadherin has been shown (Nawroth et al., 2002).  Surprisingly, our data showed a 
very unique mutually exclusive interaction (Figure 5.1A and B) in both confluent and 
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isolated cells.  We believe that this relationship between tyrosine phosphorylation and AJ 
opening had an effect on our data because we observed localization and no-localization in 
both confluent and not very confluent cells when with VE-Cadherin and Tie2 complex.   Our 
FRET data of this complex showed a co-localization with FRET efficiency of 14.9±1.3 SEM 
and a significant part of our data showed no co-localization of the protein in both HEK293 
and U2OS cell lines.  Similarly, the numeric part of the lifetime data was not promising but 
the lifetime distribution histogram clearly showed the quenching of the donor in the 
presence of the acceptor and possible occurrence of FRET between VE-Cadherin and Tie2.  
For immunoprecipitation studies, crude protein lysates were prepared from TIME cells 
expressing endogenous Tie2 and VE-Cadherin.  As shown in Figure 4.3 when used for 
immunoprecipitation, we were able to precipitate endogenous Tie2 and VE-Cadherin.   
In addition, we made several attempts to co-express all three, VE-PTP, VE-Cadherin, 
and Tie2 in HEK293.  VE-PTP-FL-sYFP2 and VE-Cadherin-mTQ was co-expressed with Tie2 
fused to myc.  We observed mutual exclusive localization of the protein (Figure 5.3) but 
unfortunately Tie2-myc appeared to be toxic to cells and we were unable to obtain 
statistically enough data to fully characterize the protein behavior.  The failure to detect 
FRET from a pair of labeled proteins may not always mean the absence of interaction 
between them.  Mainly because we are working with overexpressed system and there are 
many factors that have effects on our data such as the transfection efficiency, fluorophore 
concentrations, intensity, environment and etc.  
Another focus of our studies was to better understand the Neuropilin/Plexin/ 
Semaphorin system. This signaling system is involved in the regulation of various 
developmental events including axonal extension, cell migration in the nervous system, 
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growth of endothelial cells, and cardiac development.  Neuropilins are known for their 
ability to bind to class 3 semaphorins using plexin as a co-receptor to activate downstream 
signal transduction cascades (Capparuccia at el., 2009).  Not much is known about the 
effect of Sema3D on Nrp/plexin complex.  The aim of our study is to characterize the 
protein localization, morphological changes and FRET signal upon of this complex upon 
stimulation with Sema3D.  We first examined several constructs of Nrp and plexin with 
various linker lengths to determine the optimal pair that gave  the best FRET efficiency 
signal (13.8%±5.3 SEM, this is a negative control with no Sema added). HEK293 cells 
expressing Nrp-1 and PlexinA1 showed a morphology change after addition of Semaphorin 
3D.  Based on our observations, Sema3D caused expansion in size and rounding up of Nrp-
1/PlexinA1 expressing cells.   In addition, we observed that the protein dissociated and 
clustered in some parts of the cells and the FRET signal in the two experiments we 
performed was 22.5%±4.5 SEM upon stimulation with Sema3D. (Figure 6).  Based on our 
observations Sema3D has effects on the association of Nrp and plexin.  As we discussed in 
the introduction Nrps have the ability to bind to both semaphorins and VEFG, which are 
two structurally and functionally, unrelated ligands suggesting a tight collaboration 
between angiogenesis and the nervous system. In this process VE-Cadherin along with 
neuropilins plays an essential role by directing VEGF signals to the appropriate location 
and coordinating the activation of downstream molecules.  Further studies are needed to 
investigate the Nrps/Plexin complex behavior upon addition of semaphorins and VEGF.   
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